Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $19.88 Consensus Price Target from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $19.8750.

Several analysts recently weighed in on JSPR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Rodman & Renshaw started coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price objective on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in JSPR. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the first quarter worth approximately $46,000. Marex Group plc acquired a new stake in Jasper Therapeutics during the second quarter worth approximately $74,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $78,000. Panagora Asset Management Inc. acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at $35,000. Finally, Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

JSPR stock opened at $1.42 on Monday. The business’s 50-day moving average is $1.51 and its two-hundred day moving average is $1.98. The firm has a market capitalization of $39.73 million, a P/E ratio of -0.24 and a beta of 3.08. Jasper Therapeutics has a 1 year low of $1.11 and a 1 year high of $7.19.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.